Q2 FY2026 EarningsQ2 FY26 results presented a significant top-line beat but a bottom-line miss compared to consensus. Revenue of $9.3M substantially exceeded the $5.1M estimate, driven by collaboration milestones. However, GAAP EPS of -$0.93 missed the -$0.78 mean expectation due to accelerated R&D and pre-launch G&A spending. The company fortified its balance sheet to $420M, extending its cash runway through the potential 2028 commercialization of zorevunersen.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Stoke Therapeutics(STOK) the Revenue is 9.325 M (-32.51%), Beat estimate;the EBIT is -65.43 M (-139.7%), Miss estimate;the EPS is -0.93 (-132.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B32.51%
0.01B63.16%
+0.00B30.65%
EBITMiss expectations
-0.07B139.67%
-0.06B103.00%
-0.01B36.67%
EPSMiss expectations
-0.93132.50%
-0.781895.46%
-0.148237.04%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf